RxDoctor Payments Data

Hertzel Sure, MD

Internal Medicine · Elmhurst, NYNPI 1083727762

Payments from drug & device makers

$90,714in general payments, 2019–2025

Across 1,096 payments — averaging $82.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$72K
  • AstraZeneca$3K
  • AbbVie$2K
  • GSK$2K
  • Novo Nordisk$1K
  • Gilead$1K
  • plus $9K from 54 others

What the payments were for

  • Speaking & faculty fees$66,74074%
  • Food & beverage$23,94426%
  • Education$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer136$71,553
AstraZeneca116$2,665
AbbVie(2 entities)145$2,432
GSK112$2,243
Novo Nordisk80$1,494
Gilead56$1,153
Amgen(2 entities)40$1,122
Johnson & Johnson62$1,002
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC69$955
Lilly USA, LLC30$571
Cognoa, Inc.4$570
Pfizer24$481
Sanofi-aventis U.S. LLC19$401
Sanofi13$383
Merck25$372
Novartis25$369
E.r. Squibb & Sons, L.L.C.8$273
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)11$213
Amarin Pharma, Inc.9$179
Global Blood Therapeutics, Inc.9$173
Avanir Pharmaceuticals, Inc.7$140
Astellas Pharma US Inc5$133
Boehringer Ingelheim6$131
Teva Pharmaceuticals USA, Inc.7$113
Ironwood Pharmaceuticals, Inc6$113
Mannkind Corporation5$96
Sumitomo Pharma America, Inc.4$96
Daiichi Sankyo Inc.4$80
Biohaven Pharmaceuticals, Inc.3$74
Regeneron Healthcare Solutions, Inc.4$73
Corcept Therapeutics3$65
Exact Sciences3$65
Axsome Therapeutics, Inc.2$63
Xeris Pharmaceuticals, Inc.3$52
Abbott2$51
Renalytix AI, Inc.2$45
Scilex Pharmaceuticals Inc.2$44
Supernus Pharmaceuticals, Inc.2$43
Amphastar Pharmaceuticals, Inc.2$43
Phathom Pharmaceuticals, Inc.2$43
Indivior Inc.2$42
EPI Health, LLC2$36
Vertex1$33
Biohaven Pharmaceutical Holding Company Ltd.2$31
Alkermes, Inc.2$29
Insulet Corporation1$28
Impel Pharmaceuticals Inc.1$24
Eisai Inc.1$24
Otsuka America Pharmaceutical, Inc.1$23
Shire North American Group Inc1$23
Idorsia Pharmaceuticals US Inc1$22
Nevro Corp.1$20
Scynexis, Inc.1$20
Shield Therapeutics Inc1$19
Redhill Biopharma Inc.1$19
Melinta Therapeutics, LLC1$18
ANI Pharmaceuticals, Inc.1$18
Bausch Health US, LLC1$18
Paratek Pharmaceuticals, Inc.1$18
ARS Pharmaceuticals Operations, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,714 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$177,739
Medicare patients
136
Services billed
3,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone321$234,455
Xigduo XrDapaglifloz Propaned/Metformin179$173,112
OzempicSemaglutide104$111,589
Trelegy ElliptaFluticasone/Umeclidin/Vilanter135$106,499
RybelsusSemaglutide59$91,630
TrulicityDulaglutide59$89,978
JanuviaSitagliptin Phosphate82$86,680
EliquisApixaban84$84,670
LinzessLinaclotide84$54,866
Tresiba Flextouch U-200Insulin Degludec52$48,853
BiktarvyBictegrav/Emtricit/Tenofov Ala13$48,442
MounjaroTirzepatide30$45,314
Breztri AerosphereBudesonide/Glycopyr/Formoterol48$42,880
FarxigaDapagliflozin Propanediol33$42,752
JanumetSitagliptin Phos/Metformin Hcl34$34,700

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$71,553$234,455321 claims
Novo NordiskOzempic, Rybelsus$1,494$203,219163 claims
MerckJanuvia, Janumet, Janumet Xr$372$146,134142 claims
Lilly USA, LLCTrulicity, Mounjaro$571$135,29189 claims
GSKTrelegy Ellipta$2,243$106,499135 claims
AstraZenecaBreztri Aerosphere, Farxiga$2,665$85,63181 claims
PfizerEliquis$481$84,67084 claims
AbbVieLinzess$2,432$54,86684 claims
GileadBiktarvy$1,153$48,44213 claims
Boehringer IngelheimSynjardy Xr, Jardiance$131$45,37145 claims
AmgenProlia$1,122$31,01019 claims
Johnson & JohnsonXarelto$1,002$30,35428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Elmhurst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →